March 12, 2021
MSD said on March 11 that it has filed its anti-PD-1 antibody Keytruda (pembrolizumab) for an additional indication of advanced/relapsed tumor mutational burden-high (TMB-H) solid tumors that have progressed following chemotherapy. TMB-H is defined as 10 mutations per megabase or...read more